Skip to main content
Journal cover image

Antibacterial Resistance Leadership Group 2.0: Back to Business.

Publication ,  Journal Article
Chambers, HF; Evans, SR; Patel, R; Cross, HR; Harris, AD; Doi, Y; Boucher, HW; van Duin, D; Tsalik, EL; Holland, TL; Pettigrew, MM; Tamma, PD ...
Published in: Clin Infect Dis
August 16, 2021

In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

August 16, 2021

Volume

73

Issue

4

Start / End Page

730 / 739

Location

United States

Related Subject Headings

  • Microbiology
  • Leadership
  • Gram-Positive Bacteria
  • Gram-Negative Bacteria
  • Drug Resistance, Bacterial
  • Anti-Bacterial Agents
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
  • 06 Biological Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chambers, H. F., Evans, S. R., Patel, R., Cross, H. R., Harris, A. D., Doi, Y., … Fowler, V. G. (2021). Antibacterial Resistance Leadership Group 2.0: Back to Business. Clin Infect Dis, 73(4), 730–739. https://doi.org/10.1093/cid/ciab141
Chambers, Henry F., Scott R. Evans, Robin Patel, Heather R. Cross, Anthony D. Harris, Yohei Doi, Helen W. Boucher, et al. “Antibacterial Resistance Leadership Group 2.0: Back to Business.Clin Infect Dis 73, no. 4 (August 16, 2021): 730–39. https://doi.org/10.1093/cid/ciab141.
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, et al. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clin Infect Dis. 2021 Aug 16;73(4):730–9.
Chambers, Henry F., et al. “Antibacterial Resistance Leadership Group 2.0: Back to Business.Clin Infect Dis, vol. 73, no. 4, Aug. 2021, pp. 730–39. Pubmed, doi:10.1093/cid/ciab141.
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clin Infect Dis. 2021 Aug 16;73(4):730–739.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

August 16, 2021

Volume

73

Issue

4

Start / End Page

730 / 739

Location

United States

Related Subject Headings

  • Microbiology
  • Leadership
  • Gram-Positive Bacteria
  • Gram-Negative Bacteria
  • Drug Resistance, Bacterial
  • Anti-Bacterial Agents
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
  • 06 Biological Sciences